Head-to-Head: Impax Laboratories VS. SCYNEXIS

Impax Laboratories (NASDAQ:$IPXL) and SCYNEXIS (NASDAQ:$SCYX) are both small-cap companies competing in the medical sector. So how do these two rivals stack up against each other? Let’s look at the numbers.

Profitability

Impax Laboratories has a Return on Equity of 9.05% and a Return on Assets of 3.20%, with Net Margins of -71.08%. SCYNEXIS has a Return on Equity of -64.04% and a Return on Assets of -37.19%, with Net Margins of -9,648.47%. This gives Impax the clear edge in profitability.

Earnings & Valuation

Impax Laboratories currently boasts a Gross Revenue of $812.82 million, a Price/Sales Ratio of 1.79, and an EBITDA of $144.42 million. They also have an EPS of -$8.07 and a Price/Earnings Ratio of -2.52. SCYNEXIS, on the other hand, has a Gross Revenue of $256,999.00, a Price/Sales Ratio of 250.58, and an EBITDA of -$25.04 million.

Looking at this, we can see that Impax Laboratories has higher revenue and earnings than its competitor.

What are Analysts Saying?

Impax Laboratories currently has 9 ‘Hold’ ratings, 5 ‘Buy’ ratings, and 1 ‘Sell’ rating, for an aggregate of 2.27. SCYNEXIS currently has 1 rating of ‘Strong-Buy’ and 1 rating of ‘Hold’ for an aggregate rating score of 3.00.

Impax has a consensus price target of $19.67. This could indicate a potential downside of 3.12%. SCYNEXIS, on the other hand, has a target price of $11.25, suggesting a potential upside of 366.80%. This shows that equities analysts clearly believe that SCYNEXIS is more favorable, given its stronger consensus rating and higher probably upside.

What are the Risks?

Impax Laboratories is 17% more volatile than the S&P 500, with a beta of 1.17. Meanwhile, SCYNEXIS is 68% less volatile than the S&P 500, a beta of 0.32. This indicates that SCYNEXIS is slightly superior when it comes to risk.

Insider & Institutional Ownership

Ownership by institutions and insiders can indicate that the respective groups have faith that the company will experience an upswing or perform well in the future. Impax Laboratories is currently 86.3% owned by institutes and 3.2% owned by company insiders. SCYNEXIS is 36.8% owned by institutions and 4.0% owned by insiders.